Kadmon Corporation Reveals Promising Data on Experimental Lupus Therapy
Kadmon Corporation, LLC, a biopharmaceutical company focused on autoimmune, fibrotic, metabolic diseases and the oncology field, recently announced promising preclinical data on its KD025 drug in the treatment of systemic lupus erythematosus (SLE). The data was presented in May 2015 at the American Association of Immunologists (AAI) Annual…